Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

CAS  PubMed  Article  Google Scholar 

Strik HM, Marosi C, Kaina B et al (2012) Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep 12:286–293

CAS  PubMed  Article  Google Scholar 

Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C and Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017, Neuro-Oncology. 2020 22(1)

Singh N, Miner A, Hennis L, Mittal S (2021) Mechanisms of temozolomide resistance in glioblastoma—a comprehensive review. Cancer Drug Resist 4:17–43

CAS  PubMed  PubMed Central  Google Scholar 

Yi GZ, Huang G, Guo M et al (2019) Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain 142(8):2352–2366. https://doi.org/10.1093/brain/awz202

Article  PubMed  PubMed Central  Google Scholar 

Kitange GJ, Carlson BL, Schroeder MA et al (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11(3):281–291. https://doi.org/10.1215/15228517-2008-090

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198–210

PubMed  PubMed Central  Article  Google Scholar 

Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R (2015) Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol 47(2):417–428

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wickström M, Dyberg C, Milosevic J et al (2015) Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6:8904

PubMed  Article  CAS  Google Scholar 

Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, Pollok KE, Fishel ML, Rickus JL (2018) Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. PLoS ONE 13(3):e0194183

PubMed  PubMed Central  Article  CAS  Google Scholar 

Yuan Y, Xue X, Guo RB, Sun XL, Hu G (2012) Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther 18(7):536–546

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chu CW, Ko HJ, Chou CH et al (2019) Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling pathway in glioma cells. Int J Mol Sci 20(3):473

CAS  PubMed Central  Article  Google Scholar 

Liu T, Li A, Xu Y, Xin Y (2019) Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Oncol Rep 41:1883–1892

CAS  PubMed  Google Scholar 

Li C, Liu Y, Liu H et al (2015) Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cell Physiol Biochem 35:1303–1316

CAS  PubMed  Article  Google Scholar 

Li Zy, Li Qz, Chen L et al (2016) Histone deacetylase inhibitor RGFP109 overcomes temozolomide resistance by blocking NF-κB-dependent transcription in glioblastoma cell lines. Neurochem Res 41:3192–3205

CAS  PubMed  Article  Google Scholar 

Hanna C, Kurian KM, Williams K et al (2020) Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol 22(12):1840–1850

CAS  PubMed  PubMed Central  Article  Google Scholar 

Su JM, Thompson P, Adesina A et al (2014) A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol 16(12):1661–1668

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zou HY, Li Q, Engstrom LD et al (2015) PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA 112(11):3493–3498

CAS  PubMed  PubMed Central  Article  Google Scholar 

Makhlin I, Salinas RD, Zhang D et al (2019) Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. CNS Oncol. 8(3):CNS43

CAS  PubMed  PubMed Central  Article  Google Scholar 

García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, Carrillo E, Marchal JA, García MÁ (2021) The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci 23(1):370

PubMed  PubMed Central  Article  CAS  Google Scholar 

Gilbert MR, Gonzalez J, Hunter K et al (2010) A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 12(11):1167–1172

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dave N, Sengaonkar V, Chow LML, Kendler A, LaSance K (2017) Desai PB ATPS-13 Aromatase expression in high grade gliomas: a potential new target for therapy. Neurooncol 17(5):v20–v21

Google Scholar 

Tivnan A, Heilinger T, Ramsey JM et al (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, LTZ, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:16605–16620

PubMed  PubMed Central  Article  Google Scholar 

Duenas Jimenez JM, Candanedo Arellano A, Santerre A et al (2014) Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas. J Neurooncol 119:275–284

CAS  PubMed  Article  Google Scholar 

Dave N, Chow LM, Gudelsky GA, LaSance K, Qi X, Desai PB (2015) Preclinical pharmacological evaluation of LTZ as a novel treatment for gliomas. Mol Cancer Ther 14:857–864

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dave N, Gudelsky GA, Desai PB (2013) The pharmacokinetics of LTZ in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol 72:349–357

CAS  PubMed  Article  Google Scholar 

Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, Yan H, Dhruv HD, Berens ME, Wang Q, Marin BM, Klee EW, Califano A, LaChance DH, Eckel-Passow JE, Verhaak RG, Sulman EP, Burns TC, Meyer FB, O’Neill BP, Tran NL, Giannini C, Jenkins RB, Parney IF, Sarkaria JN (2020) Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res 26(5):1094–1104

CAS  PubMed  Article  Google Scholar 

Xu X, Veenstra TD (2012) Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med 4(4):31

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

CAS  PubMed  Article  Google Scholar 

Firsanov D, Solovjeva L, Lublinskaya O, Zenin V, Kudryavtsev I, Serebryakova M, Svetlova M (2017) Rapid detection of γ-H2AX by flow cytometry in cultured mammalian cells. Methods Mol Biol 1644:129–138

CAS  PubMed  Article  Google Scholar 

Wilson KM, Mathews-Griner LA, Williamson T, Guha R, Chen L, Shinn P, McKnight C, Michael S, Klumpp-Thomas C, Binder ZA, Ferrer M, Gallia GL, Thomas CJ, Riggins GJ (2019) Mutation profiles in glioblastoma 3D oncospheres modulate drug efficacy. SLAS Technol 24(1):28–40

CAS  PubMed  Article  Google Scholar 

Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15(22):7092–7098

CAS  PubMed  PubMed Central  Article  Google Scholar 

Volovetz J, Berezovsky AD, Alban T et al (2020) Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells. Cell Death Dis 11(2):152 (Published 2020 Feb 26)

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gómez-Oliva R, Domínguez-García S, Carrascal L et al (2021) Evolution of experimental models in the study of glioblastoma: toward finding efficient treatments. Front Oncol 10:614295 (Published 2021 Jan 29)

PubMed  PubMed Central  Article  Google Scholar 

Center for Drug Evaluation and Research, U.S. FDA, Clinical Pharmacology Review for Femara (NDA 20–726), 1997

Pritts EA, Yuen AK, Sharma S, Genisot R, Olive DL (2011) The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulation. ISRN Obstet Gynecol

Buzdar AU (2003) Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 9:468S-S472

CAS  PubMed  Google Scholar 

Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, LTZ, and exemestane. Cancer 95:2006–2016

CAS  PubMed  Article